The BCR-ABL; breakpoint cluster region-Abelson point mutation T315I is resistant to ABL tyrosine kinase inhibitors. However, axitinib, a vascular endothelial growth factor receptor inhibitor, is effective against this mutation. In this study, we investigated axitinib activity against ponatinib-resistant cells and found that axitinib inhibited cellular growth and apoptosis in Ba/F3 T315I-mutant cells and T315I-mutant primary samples, but not in ponatinib-resistant Ba/F3 cells and primary samples. Thus, an alternative strategy may be required to improve the prognosis of Philadelphia-chromosomepositive leukemia patients harboring BCR-ABL point mutations.
Letters to the editor
The BCR-ABL1 fusion gene is a causative oncogene in chronic myeloid leukemia (CML) and 30-50 % of acute lymphoblastic leukemia cases [1, 2] . Although ABL tyrosine kinase inhibitors (ABL TKIs) such as imatinib, nilotinib, dasatinib, and bosutinib have improved CML treatment [3] , such therapies cannot cure patients with Philadelphia chromosome (Ph)-positive leukemia because of leukemia stem cells [4] . Moreover, some patients develop BCR-ABL point mutations and become resistant to ABL TKI therapy [5] . In particular, the ABL kinase domain mutation T315I is resistant to imatinib and second-generation ABL TKIs (e.g., nilotinib, dasatinib, and bosutinib). Accordingly, this mutation is often found in patients with TKIresistant disease [6] . A third-generation ABL TKI, ponatinib, and omacetaxine which is a semisynthetic form of homoharringtonine, was recently developed [7] . Ponatinib is a potent oral tyrosine kinase inhibitor that affects both unmutated and mutated BCR-ABL [8] ; it is effective against T315I-mutant cells and has been approved for TKI-resistant or intolerant CML and Ph-positive ALL patients. Omacetaxine is approved for the treatment of chronic or accelerated-phase CML refractory to TKIs [7] .
Recently, the vascular endothelial growth factor receptor (VEGFR) inhibitor axitinib was found to exhibit antileukemic activity against T315I-mutant disease. In the comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS) trial [9] , axitinib improved progression-free survival (PFS) compared to sorafenib, which is an all-multikinase inhibitor that blocks angiogenesis targets [10] , in patients with advanced renal cell carcinoma (RCC). Axitinib was approved for the treatment of advanced RCC. Axitinib is an orally active and potent TKI of VEGFRs 1, 2, and 3 and inhibits BCR-ABL1, especially the T315I variant, via a distinct binding conformation [11] . In this study, we investigated whether axitinib could suppress ponatinibresistant compound-mutant cells harboring the T315I mutation. A 72-h axitinib treatment inhibited the growth of Ba/F3 T315I cells (Fig. 1a) . Immunoblot analysis of axitinib-treated cells revealed dose-dependent decreases in BCR-ABL, the downstream molecule Crk-L, and ribosomal S6 protein phosphorylation and increases in caspase 3 and Poly (ADP-ribose) polymerase (PARP) activity (Fig. 1b, c, e) . Ponatinib and axitinib also induced apoptosis, significantly increased caspase activity (Fig. 1d) , and reduced Akt activity (Fig. 1f) .
In contrast, clinically available concentrations of axitinib did not inhibit the growth of ponatinib-resistant Ba/F3 cells (Fig. 1a) . Immunoblot analysis revealed that BCR-ABL, Crk-L, and S6 kinase phosphorylation were not inhibited by axitinib or ponatinib (Fig. 1b, e) . Similarly, no increase in caspase activity or decrease in Akt activity was observed following axitinib treatment (Fig. 1c, f), and neither ponatinib nor axitinib affected apoptosis in these cells (Fig. 1d) .
A
We next evaluated primary T315I-mutant and ponatinibresistant compound-mutant samples. Axitinib potently inhibited the growth of T315I-mutant primary cells in a dose-dependent manner (Fig. 1g) . Immunoblot analysis further revealed reduced Crk-L and S6 kinase phosphorylation after axitinib or ponatinib treatment (Fig. 1i) . In contrast, the growth of ponatinib-resistant primary cells was not affected by ponatinib or axitinib (Fig. 1h) . Immunoblotting revealed that neither ponatinib nor axitinib affected the phosphorylation of Crk-L and S6 kinase in ponatinibresistant cells (Fig. 1i) .
In CML, ABL TKI resistance is frequently caused by ABL kinase domain mutations. The T315I mutation is resistant to all ABL TKIs except ponatinib. However, we previously described ponatinib-resistant cells resulting from a BCR-ABL compound mutation [12] . Although axitinib, which is currently being investigated for efficacy in patients with Ph-positive T315I-mutant leukemia, induced apoptosis in T315I-mutant cells, it was ineffective against cells with a compound mutation including T315I. An alternative strategy will be required to improve the prognosis of patients with Ph-positive, BCR-ABL-mutant leukemia. Current evidence to direct the management of ABL TKI-resistant disease, particularly those harboring T315I and compound mutations, is limited. New molecular-targeted drugs and an understanding of ABL TKI resistance mechanisms are required to apply an appropriate therapeutic approach.
Abbreviations CML: chronic myeloid leukemia; Ph: Philadelphia chromosome; TKI: tyrosine kinase inhibitor; VEGFR: vascular endothelial growth factor receptor.
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